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Abstract 
Postoperative nausea and vomiting (PONV) is a complication that affects up to 30% of 
the patients undergoing general surgery. This complication can be dangerous for patients, 
increase recovery time and decrease patient satisfaction scores. There are many different 
medications that have been used to prophylactically treat PONV including haloperidol. A 
systematic review was conducted to determine the efficacy of haloperidol as an 
antiemetic. Databases were searched and inclusion and exclusion criteria were applied to 
finalize the articles included. The PRISMA framework was used to guide the review and 
a total of five studies were critically analyzed. Two data collection tables were created for 
each article, one that illustrated the design of the study and one that illustrated the results. 
The CASP checklist was utilized to critically appraise each article. Finally, a cross study 
analysis was conducted to compare the studies. Haloperidol was studied alone and in 
combination with other antiemetic medications. Overall, these studies showed a decrease 
in PONV in patients medicated with haloperidol. Using haloperidol prophylactically, 
especially when utilized with multiple medications, decreased episodes of vomiting and 
levels of nausea. Haloperidol can be a useful and safe medication that anesthesia 
providers may utilize to prevent PONV. Further research is needed to study the impact on 
general surgery procedures and with larger samples.   
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Haloperidol and Postoperative Nausea and Vomiting: A Systematic Review 
Background/Statement of the Problem 
Post-operative nausea and vomiting (PONV) has been a continuous problem for 
patients recovering from surgery. Postoperative nausea and vomiting is defined as any 
nausea, retching, or vomiting in the 24 period after surgery (Flood, Rathmell, & Shafer, 
2015).  In 1914, the first journal of anesthesia published an article about prophylactically 
treating PONV. Even though it has been a source of conversation since then, it remains 
one of the most common complications of general anesthesia (Nagelhout & Plaus, 2014). 
Incidence as high as 30% in all patients and as high as 80% in cases where the patient 
was at high risk for PONV are reported (Pierre & Whelan, 2013).  
This common complication often increases recovery time, which may lead to an 
unexpected hospital stay or increased length of stay after the procedure (Flood et al., 
2015). Vomiting or retching after surgery can be dangerous for the patient and cause 
further complications such as suture dehiscence and aspiration (Nagelhout & Plaus, 
2014). Postoperative nausea and vomiting is very uncomfortable for the patient and 
contributes to dissatisfaction scores for anesthesia providers (Flood et al., 2015). Patients 
have even ranked PONV as the most important clinical anesthesia complication to avoid, 
putting it ahead of other complications such as pain, intraoperative recall and gagging on 
the endotracheal tube (Flood et al). 
When a patient goes under general anesthesia, there are many factors that can 
contribute to PONV. These include the medications used, such as the volatile anesthetics 
and opioids, as well as other factors such as the patient’s anxiety, motion and surgical 
manipulation (Pierre & Whelan, 2013). Volatile anesthetics have been shown to increase 
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PONV two-fold and nitrous oxide has also been shown to have an increased risk. Adding 
opioids throughout the case can increase PONV in a dose-dependent manner (Pierre & 
Whelan). All of these combined provide an environment where PONV can easily occur.  
 There are identified risk factors that place patients are increased risk for PONV. 
These risks are divided into patient specific, anesthesia related, and surgery related 
(Nagelhout & Plaus, 2014). Patient specific risk factors include female gender, age less 
than 50, nonsmokers, history of PONV and history of motion sickness. Anesthetic related 
factors include use of volatile anesthetics, use of nitrous oxide and 
intraoperative/postoperative use of opioids. Surgery related risk factors include the 
duration of the surgery being more than one hour and the type of surgery. Laparoscopic 
surgery has been identified as one of the surgical procedures with a high incidence of 
PONV (Nagelhout & Plaus). When a patient has several risk factors, it can increase the 
risk of PONV up to 80% (Pierre & Whelan, 2013). 
 To prevent the patient from having to experience PONV, a prophylactic approach 
has been used. To prophylactically treat a patient, especially one who has been 
determined as high risk, a multimodal approach works well due to the complexity of 
activating the vomiting center (Pierre & Whelan, 2013). Postoperative nausea and 
vomiting is controlled in the brain at what is called the vomiting center. This is in the 
medulla oblongata and contains the nucleus of the tractus solitaries (NTS). Multiple 
neurotransmitters control the activity of this vomiting center. These neurotransmitters are 
dopamine, serotonin, substance P, acetylcholine, gamma-aminobutyric and cannabinoids. 
PONV can also be activated through the chemoreceptor trigger zone (CRTZ) when the 
body detects noxious chemicals (Flood et al., 2015). The different medications can work 
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independently to prevent nausea and vomiting, but when used in combination they also 
have additive effects (Pierre & Whelan, 2013). 
One of these medications is haloperidol, which is a butyrophenone, and has an 
antagonistic effect on the D2 dopamine receptors. Haloperidol is primarily used to treat 
schizophrenia and other psychiatric disorders but has other uses, such as a treatment for 
intractable hiccups. It also has antiemetic properties (Flood et al., 2015). Haloperidol 
does have side effects, especially at higher doses, such as cardiac arrhythmias, 
prolongation of the QTc interval, sedation, and extrapyramidal symptoms. These side 
effects provide some risk with using haloperidol as a prophylactic medication (Pierre & 
Whelan, 2013).  
The purpose of this systematic review is to review current evidence of how 
haloperidol effects postoperative nausea and vomiting in patients who have undergone a 
laparoscopic surgical procedure.  
Next, a review of the literature will be presented.  
  
4 
 
Literature Review 
 A review of the literature was conducted to examine information about PONV 
and the effects of haloperidol. Databases searched were PubMed, CINAHL, Medline, and 
google scholar.  Search words included postoperative nausea and vomiting, treatment, 
causes, risk factors, haloperidol and laparoscopic surgery. Evidence-based reviews, 
randomized control trials, guidelines, quasi-experimental studies, and non-experimental 
studies were included in this literature review.  
Laparoscopic Surgical Procedures 
 Laparoscopic surgery has greatly changed the way general, gynecological and 
urological surgery is done. The laparoscopic cholecystectomy is not only the most 
common laparoscopic surgical procedure performed, it is also now considered the gold 
standard for removing the gallbladder (Chamberlain & Sakpal, 2009). A laparoscopic 
surgical procedure is considered a minimally invasive surgical procedure (Nagelhout & 
Plaus, 2014). This allows a surgeon to perform a surgical procedure with less blood loss, 
decreased pain, and a quicker recovery for the patients. Although laparoscopic technique 
has been changing clinical practice for approximately 30 years, it was first used in 1901 
for an endoscopic examination of the peritoneal cavity by a German surgeon. For 70 
years after that surgery, there were surgeons who attempted to use a laparoscopic method. 
However, there were many complications during those times such as cautery injuries and 
perforations. As technology advanced, especially with videoscopic imaging being 
developed in the 1980’s, the first laparoscopic cholecystectomy was performed with 
video assistance by a French surgeon in 1988. With this successful procedure, the health 
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care community began to pay attention to utilizing laparoscopic procedures (Nagelhout & 
Plaus). 
 Now that these procedures can be done with video assistance, there are many 
advantages to them. Laparoscopic surgeries tend to be safer, less painful, minimally 
invasive and have a faster recovery time to normal function (Nagelhout & Plaus, 2014). 
These procedures are usually associated with less blood loss, fewer blood transfusions, 
and less postoperative opioid requirements (Butterworth, Mackey & Wasnick, 2013).  
 Although there are many benefits to laparoscopic surgical procedures, they are 
also complex and do have their own complications (Nagelhout & Plaus, 2014). To 
perform a laparoscopic procedure, the surgeon creates a pneumoperitoneum where air or 
gas is instilled into the peritoneal cavity under pressure. This creates an area where the 
surgeon can visualize the field they are working on. The creation of this 
pneumoperitoneum is responsible for most of the complications seen with laparoscopic 
surgical procedures, including vascular or bowel injury and hemodynamic changes. 
These can be seen intraoperatively as well as postoperatively (Nagelhout & Plaus). The 
other complication frequently seen with laparoscopic procedure is increased incidence of 
nausea and vomiting which is believed to be from the increased air or gas in the 
peritoneal cavity causing irritation (LiveStrong, 2015). Combining this irritation with 
other risk factors for PONV, such as anesthetic gases or opioids, creates a greater 
occurrence of PONV (LiveStrong). 
Postoperative Nausea and Vomiting 
 Postoperative nausea and vomiting is one of the most common postoperative 
complications seen. It is defined as any nausea, retching, or vomiting occurring during 
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the first 24 hours after surgery (Pierre & Whelan, 2013).  It is seen in 30% of patients 
undergoing general anesthesia, and up to 80% of patients who have been identified as 
high risk patients (Pierre & Whelan). Experiencing PONV can lead to prolonged 
recovery, unplanned or prolonged hospital admissions, poor satisfaction scores, and 
higher patient cost (Smith, H., Smith, E., & Smith, B., 2012). This common complication 
is disliked by patients so intense that one study showed that patients ranked vomiting as 
more undesirable than gagging on the tracheal tube, incisional pain, recall, residual 
weakness, shivering, sore throat, and somnolence. Patients stated they were even willing 
to pay between $56-100 for hypothetical effective antiemetic prophylaxis (Smith et al.). 
Also, it puts the patient at risk for further complications such as aspiration pneumonia, 
Boerhaave’s syndrome, subcutaneous emphysema, pneumothorax, rupture of the trachea, 
loss of vision, and suture dehiscence (Rusch, Eberhart, Wallenborn, & Kranke, 2010). 
 Postoperative nausea and vomiting is controlled in the body from the vomiting 
center. This is an area in the medulla that receives signals and can trigger nausea and/or 
vomiting. The vomiting center also communicates with the chemoreceptor trigger zone 
which can trigger vomiting. These two areas have multiple receptors, which can cause 
them to be activated in many different ways. The receptors found here are histamine, 
serotonin, cholinergic, neurokinin-1 and D2 dopamine receptors. Due to the multiple 
ways these centers can be activated, there are many different ways which a patient can be 
treated for PONV (Chatterjee, Rudra & Sengupta, 2011). 
 It is very important to prevent PONV whenever possible so that patients do not 
have to experience this complication. One study stated that while laparoscopic procedures 
usually are associated with short periods of hospitalization, PONV is being seen as the 
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most common reason for prolongation of hospital stay after a laparoscopic 
cholecystectomy (Akkurt et al., 2009). This study compared recovery time of patients 
receiving propofol for anesthesia and patients receiving a general anesthetic gas, 
desflurane. There was a total of 68 patients who were included in this study. All patients 
were in the ASA class I or II and had a laparoscopic cholecystectomy. Five patients were 
excluded from this study, with 63 remaining who were then divided into two groups. In 
the propofol group, there was a significant decrease in PONV which coincided with a 
decrease in hospitalization time. Only two patients (6.7%) in the propofol group had 
vomiting episodes, while 16 patients (53.3%) in the desflurane group did. This was found 
to be statistically significant with P < 0.005. Also, the patient satisfaction scores were 
significantly higher in the group that did not receive desflurane (P <0.001) (Akkurt et 
al.). 
Risk Factors for Postoperative Nausea and Vomiting and Scoring Systems 
 There are identified factors that can predict if a patient will be at higher risk for 
developing nausea and vomiting. There are patient specific factors, anesthesia related 
factors and surgery specific factors (Pierre, Benais & Pouymayou, 2002). Patient specific 
risk factors include the female gender, age less than 50, nonsmokers, and a history of 
PONV or motion sickness. Anesthesia related risk factors include the use of volatile 
anesthetics, nitrous oxide, and opioids. Surgery related risk factors include the duration of 
the surgery and the type of surgery (Nagelhout & Plaus, 2014). 
There have been several different scoring systems utilized to determine a patient’s 
risk level. One of these scoring systems is called the Sinclair-score (Pierre et al., 2002).  
This system takes into account all three kinds of risk factors. Another scoring system is 
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called the Apfel-score which examines four specific risk factors including female gender, 
previous history of PONV or motion sickness, non-smoking status, and postoperative use 
of opioids (Pierre et al.). Health care facilities have a protocol on which scoring systems, 
if any, are used to identify high risk patients and how those patients are managed. Some 
facilities lean towards a risk factor directed prophylaxis treatment, while other facilities 
have a set order for patients to be prophylactically treated (Wolf et al., 2016). 
 In a study that compared these two scoring systems, five hundred consecutive 
adult patients who were undergoing general anesthesia for a throat, thyroid, breast or 
gynecological procedure were included (Pierre et al., 2002). The authors excluded 
patients who had been premedicated for nausea and vomiting, which left 428 patients. Of 
those patients 50% experienced PONV. It was found that the area under the receiver 
operating characteristic (ROC)-curve was significantly greater for the Apfel scoring 
system as compared to the Sinclair-scoring system, 0.71 vs 0.64. An area under the ROC-
curve of 1.0 represents a perfect discrimination in patients. Thus, these areas under the 
ROC-curve indicate that the Apfel scoring system is better at predicting the likelihood of 
PONV. The Apfel scoring system is relatively simple and easy for health care workers to 
use and help prevent PONV in high risk patients (Pierre et al.). 
Risk Factor-Directed Prophylaxis 
 There are various theories about how risk factors effect prophylactically treating a 
patient. Some providers believe that all patients regardless of their risk factors should be 
treated liberally for PONV, while others believe that the use of any medication should be 
patient specific and based on their risk factors (Wolf et al., 2016). Wolf et al. examined 
the effectiveness of treating patients based on their risk factors for PONV. The study 
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included 92 patients who had undergone strabismus surgery and included a mix of adult 
and pediatric patients. The Apfel-scoring system was used to determine if the patient was 
high risk. If the patient scored a 3-4 on the scale they were prophylactically treated with a 
multimodal approach which included multiple medications that effected different 
receptors. Their surgeries were done without a general anesthetic gas. Overall, 45 patients 
(49%) were found to be in the high-risk category. There were 47 patients (51%) that were 
put into the low-risk category. Out of all 92 participants, there were 16 (17%) who 
experienced PONV. The adults that were high risk had an incidence of 8% (n = 4) of 
PONV. The children who were in the high risk category had a 9% (n = 4) incidence of 
PONV. Adults who were determined to be lower risk had an incident of 21% (n = 10) and 
children had an incidence of 38% (n = 17). The study concluded with advocating for a 
more liberal use of prophylactic medications regardless of what the patients risk score 
was based on how high PONV was even in the low risk group (Wolf et al.). 
 An evidence-based review discussed prophylactically treating patients for PONV 
based on risk factors (Rusch et al., 2010). The authors stated that PONV is a significant 
problem that should be adequately prevented and treated quickly if it occurs.  The highest 
risk factors were identified as female gender, history of PONV or motion sickness, use of 
opioids during and after surgery, use of inhalation anesthetics and nitrous oxide and the 
duration of the surgery. This review focused on how risk-adapted prophylaxis compared 
to a fixed prophylaxis. It was stated that exclusively using a risk-adapted method did not 
provide any greater benefit than a fixed method where every patient is treated to prevent 
PONV. It also stated that patients that did fall into the high-risk categories required more 
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than one drug to prevent PONV and recommended that they should always be treated 
with a multimodal prophylactic method (Rusch et al.).  
Multimodal Prophylaxis of Postoperative Nausea and Vomiting 
 It has been shown that utilizing a multimodal approach to PONV can be very 
effective, even in patients that are at high risk. Gan et al. (2014) presented consensus 
guidelines for the management of PONV. These guidelines had eight goals: to understand 
who is at risk for PONV; establish factors that reduce these risks; determine the most 
effective drug therapy for prophylaxis; ascertain the best treatment for PONV, determine 
the best timing and dosage of prophylactic treatment; evaluate cost-effectiveness of 
management strategies; create an algorithm; and propose a research agenda for further 
research in this topic. 
 Due to the complex nature in which PONV occurs, it can be very beneficial to 
treat patients prophylactically with multiple drug classes (Gan et al., 2014). It has been 
shown that patients at moderate or high risk should always be treated with a combination 
of medications preoperatively and intraoperatively to prevent PONV. For example, 
serotonin antagonists, such as Zofran, have stronger antiemetic effects than antinausea 
effects where as dopamine antagonists, such as haloperidol,  have stronger antinausea 
effects (Gan et al.). It is beneficial to the patient to give these medications in combination 
to get a decreased occurrence of PONV. 
 It has also been shown that medicating patients with two medications together, 
such as dexamethasone and Zofran, has a significantly higher efficacy than when either 
drug is given alone (Gan et al., 2014). In these current guidelines, the groups of 
medications that are recommended for prophylactic treatment are 5-HT3 receptor 
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antagonists, Nk-1 receptor antagonists, corticosteroids, butyrophenones, antihistamines, 
anticholinergics, and phenothiazines. There are other medications such as propofol, 
gabapentin, and versed that have also shown antiemetic and/or antinausea properties (Gan 
et al.). 
 Chatterjee, Rudra and Sengupta (2011) stated that for patients in moderate and 
high risk groups, regional anesthesia should always be considered. This would greatly 
decrease the risk of PONV. However, if general anesthesia must be used the patient 
should receive combination antiemetic therapy. This has been shown to be superior to 
monotherapy as it allows multiple mechanisms of actions through different receptor sites 
to prevent PONV (Chatterjee et al.).  
 The effectiveness of using multiple medications to prophylactically treat PONV 
was demonstrated in a study by Biswas and Rudra (2003). This study included 120 
patients who had gone under general anesthesia for a laparoscopic cholecystectomy. The 
patients were divided into two groups, one group received only granisetron and the other 
group received granisetron and dexamethasone, both of which medications have been 
shown to decrease PONV. In the group with only the granisetron 83% (n = 50) of the 
patients did not experience PONV within the first 24 hour period after surgery. In the 
group with both the granisetron and the dexamethasone, 95% (n = 57) of the patients did 
not experience PONV. Prophylactically treating with multiple medications that work on 
different receptor sites has a greater effect (Biswas & Rudra).  
Butyrophenones 
 Butryophenones are a group of medications that work on the D2 dopamine 
receptors (Chatterjee et al., 2011). The two drugs in this class that have antiemetic 
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properties and are used to prevent PONV are droperidol and haloperidol. Prior to 2001, 
droperidol was a very popular medication used alone and in combination for prevention 
of PONV. It was used at low doses, 0.625 – 1.25 mg and it was effective. However, this 
drug class has many side effects and in 2001, the FDA released a black box warning for 
droperidol. This was due to a risk of QT prolongation which led to arrhythmias when this 
drug was used. The black box warning referred to using much higher doses of doperidol 
than would be used for PONV, however it is mandatory to now have cardiac monitoring 
on the patient when using this medication (Chatterjee et al). 
 Haloperidol also has antiemetic properties, and has been studied more since the 
black box warning on droperidol. Haloperidol was originally used to treat psychiatric 
disorders, and still is to this day. However, to prevent PONV, the dose used is 0.5-2 mg 
(Gan et al., 2014). At this lower dose other side effects such as sedation and cardiac 
arrhythmias were not seen with haloperidol though it does still carry a risk of QTc 
prolongation. Aouad et al. (2007) compared the effects of haloperidol and Zofran. This 
study included 93 females undergoing a gynecologic procedure under general anesthesia. 
When 1 mg of haloperidol was compared with 4 mg of Zofran, there was no difference in 
the QTc effect. There was also no significant difference in the PONV incidence; 40.7% 
(n = 11) of the haloperidol group experienced PONV and the Zofran group had an 
incidence of 48.2% (n = 13) (Aouad et al.).  
Another known side effect of haloperidol is extrapyramidal symptoms. However, 
a meta-analysis of haloperidol as an antiemetic showed that only one in 806 patients who 
were given 4 mg of haloperidol exhibited any extrapyramidal symptoms (Buttner, 
Walder, Elm & Tramer, 2004). Out of all the studies that the meta-analysis discussed a 
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total of 1,397 patients received haloperidol at different doses and no patients receiving a 
dose of haloperidol less than 4 mg exhibited extrapyramidal symptoms (Buttner et al). 
Since haloperidol is a dopamine antagonist it should be used with extreme caution with 
any patients who have Parkinson’s disease, restless leg syndrome, or any other disease 
that is related to a dopamine insufficiency (Flood et al., 2015).  
The Buttner et al. (2004) meta-analysis examined a total of 21 studies using 
haloperidol to treat nausea and vomiting. However, this literature review will focus on 
the evidence combined from four studies in the meta-analysis that examined the effect of 
haloperidol on preventing PONV. Intravenous dosages were tested at 5 mg and 4 mg. 
Both significantly decreased nausea and vomiting, although the antinausea effect was 
greater. With haloperidol, the average report of nausea was 16.4% (n = 90/548), whereas 
with the placebo it was 43.8% (n = 237/541). The results of this meta-analysis provide 
evidence that haloperidol is effective as an antiemetic. This systematic review will focus 
on more recent studies to evaluate the most up to date evidence on the topic. 
 Next, the theoretical framework guiding this systematic review will be discussed. 
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Theoretical Framework 
The PRISMA framework was used to guide this project. PRISMA is an evidence-
based set of items that helps authors improve the reporting in a systematic review as well 
as assess the strengths and weaknesses of a systematic review (Moher, Liberati, Tetzlaff 
& Altman, 2009). The PRISMA statement consists of a flow diagram and a checklist. 
The flow diagram is illustrated in Appendix A and guides the user through identifying, 
screening, and checking eligibility of the articles that will ultimately be included in the 
systematic review (Moher et al). 
The checklist assists the author in structuring and writing the systematic review. 
The checklist, shown in Appendix B, consists of 27 items and includes major sections of 
a systematic review and what is to be included in each section (Moher et al., 2009). This 
is helpful to make sure that every part necessary to a systematic review is included. 
Inclusion and exclusion criteria will be applied to select articles that will be analyzed. 
Utilizing PRISMA as a framework will help to create a thorough and pertinent systematic 
review (Moher et al.). 
In addition to PRISMA, the Critical Appraisal Skills Programme (CASP) was 
used to evaluate each article that was selected to be included in the systematic review. 
The purpose of CASP is to help determine the scientific integrity of the research being 
evaluated. There is a CASP checklist, illustrated in the methods section, exclusively for 
systematic reviews that will help with appraising the relevant information. There are 
three main sections to the CASP checklist. The first section is focused on the validity of 
results. There are six questions used to help the author identify if the results are valid. 
The second section is focused on what the results are. This helps to determine what each 
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study is showing. The third section is focused on how these results can be applied to 
practice (Critical Appraisal Skills Programme, 2017). 
 Next, the methods will be discussed.  
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Method 
Purpose 
 
This systematic review examined the efficacy of haloperidol in prophylactically 
treating postoperative nausea and vomiting in patients who have undergone a 
laparoscopic surgery under general anesthesia.  
Inclusion/Exclusion Criteria 
 The inclusion criteria for this systematic review were randomized control trials, 
subjects over 18 years old and must have had a laparoscopic surgical procedure with 
general anesthetic; haloperidol must have been used prophylactically for PONV, with the 
article written in English, and under 10 years old. The study must have included data on 
the incidence of PONV for 24 hours postoperatively. 
 The exclusion criteria included articles not written in English, over 10 years old, 
participants less than 18 years old, not randomized control trials, studies that did include 
laparoscopic surgical procedures and studies that do not measure incidence of PONV for 
24 hours postoperatively. 
Search Strategy 
To gather the research that is available, a detailed search included the databases 
PubMed, CINAHL, and Medline. The search words used were Haldol or haloperidol, 
postoperative nausea and vomiting, and laparoscopic surgery. The target studies were 
articles in English that were randomized control trials. The PRISMA flowchart was used 
to select articles that would be evaluated in the systematic review. On the following page 
there is the completed PRISMA four stage flow diagram, Figure 1. This demonstrates the 
selection process of articles included in the systematic review.  
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PRISMA 2009 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Completed PRISMA Flow Diagram (Moher et al., 2009). 
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Data Collection 
Once the articles that were included in the systematic review were selected, each 
article was reviewed and presented in detailed data collection tables. One table examined 
the design of the study (Table 1). The other data collection table illustrated the outcomes 
of each study (Table 2). 
 
Table 1 
Study Demographics 
Citation 
 
Purpose 
 
 
Design 
 
 
 
Sample 
 
 
Surgical 
Procedure  
 
 
Method 
  
 
 
 
Table 2 
Outcomes of the Study 
 
 
The CASP checklist for systematic reviews, illustrated in Table 3 on the next 
page, was used to critically appraise each article and determined the scientific integrity 
(Critical Appraisal Skills Programme, 2017).  This checklist helped to show how relevant 
the outcomes were from each study as well as how scientifically strong the evidence was. 
Citation    
Nausea and 
Vomiting  
 
 
Pain Scores  Adverse Side 
Effects 
Limitations 
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Table 3 
CASP Checklist 
A. Are the results of the trial valid? YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused issue?    
2. Was the assignment of patients to treatments 
randomized? 
   
3. Were all of the patients who entered the trial 
properly accounted for at its conclusion? 
   
4. Were patients, health workers, and study 
personnel “blind” to treatment? 
   
5. Were the groups similar at the start of the 
trial? 
   
6. Aside from the experimental intervention, 
were the groups treated equally? 
   
B. What are the results? 
7. How large was the treatment effect?  
8. How precise was the estimate of the 
treatment effect? 
 
C. Will the results help locally? YES  CAN’T 
TELL  
NO 
9. Can the results be applied in your context?    
10. Were all clinically important outcomes 
considered? 
   
11. Are the benefits worth the harms and costs?    
 
Descriptive Data Analysis 
 The data were synthesized into the data collection tables. A final table was created 
for a cross-study analysis (Table 4). This table combined the information from the 
different studies and compared the pertinent outcomes from all the studies together. The 
results from each individual study and the cross-study analysis was then discussed in the 
results section of the systematic review.  
           The table used for the cross-study analysis is illustrated in Table 4. 
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Table 4 
Cross-Study Analysis 
Study 
number 
Nausea & Vomiting Pain Scores  Side Effects 
1    
2    
3    
4    
5    
 
 Next, the results will be presented.  
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Results 
Five studies met the criteria for this systematic review. All of these studies 
evaluated how the use of prophylactic haloperidol effected PONV in patients who had 
undergone laparoscopic surgical procedures. The tables that illustrate the design details of 
each study can be found in Appendix C, Tables 1-5. Tables that illustrate the results of 
each study are shown in Appendix D, Tables 1-5. The critical appraisal tables for each 
study can be found in Appendix E. Appendix F illustrates the cross study analysis. 
The study conducted by Benevides, Oliveira and Aguilar-Nscimento (2012) was 
to evaluate the intensity of nausea, pain and the number of vomiting episodes on 
postoperative patients who had undergone a laparoscopic sleeve gastrectomy (Appendix 
C-1). There were 90 patients involved in this double-blind randomized control trial. 
These patients were divided into three groups. Each group was medicated with a different 
combination of prophylactic antiemetic medications. Group O received ondansetron only. 
Group DO received dexamethasone and ondansetron. Group HDO received haloperidol, 
dexamethasone and ondansetron. Throughout the procedure the anesthetic and surgical 
techniques were standardized. The postoperative diet was also standardized, advancing 
based on patients’ acceptance. The authors utilized a verbal numeric scale of nausea 
(VNSN) and a verbal numeric scale of pain (VNSP) to evaluate the patients’ pain and 
nausea. They monitored the number of vomiting or retching episodes.  
 The results of this study can be seen in Appendix D-1. There was a significant 
decrease in nausea between Group O and Group HDO (p = 0.001), with Group O having 
a mean intensity score of 4 and group HDO had a score of 1.5. With the episodes of 
vomiting, the results showed a trend towards statistical significance, with episodes of 
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vomiting lower in group HDO than group O (p = 0.052). Group HDO experienced 0.63 ± 
1.2 episodes of vomiting compared to group O 1.10 ± 1.2, and group DO 0.83 ± 2. The 
pain scores were lower in group HDO than Group O (p = 0.0.46), where the mean 
intensity score for group O was 2.2 and for Group HDO it was 1.  Some limitations to 
this study were that there was no control group for this experiment and the sample size 
was relatively small.  
The critical appraisal of this article can be seen in Appendix E-1. This table 
illustrates that the article did address the focused areas. The assignment of patients was 
randomized, all patients were accounted for at the end of the study and all personnel who 
participated in this study were blind to the treatment. All groups were treated equally 
with the exception of the experimental intervention. The number of patients in the study 
was relatively small at 90, but the results did show decreased nausea, vomiting and pain 
scores. Not all clinical outcomes were considered statistically important. 
 The study by Chu et al., (2008) evaluated the prophylactic effect of haloperidol 
given alone or in combination with dexamethasone on PONV in patients who underwent 
a laparoscopic assisted vaginal hysterectomy (Appendix C-2). This was a clinical double-
blind randomized control trial. Four hundred patients were selected for this trial; 28 of the 
patients were excluded from analysis. The patients were divided into five groups. The 
first group was Group S, the control group, in which patients were medicated with saline; 
Group D patients received droperidol; Group H patients received haloperidol; and Group 
Dx patients received dexamethasone and Group H + Dx patients received haloperidol and 
dexamethasone. All patients were medicated with the study drug 15 minutes after the 
induction of anesthesia. Anesthesia and surgical technique were standardized. The 
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authors noted that they used standard monitoring as well as measured the patients’ QT 
intervals. The authors documented PONV by including the incidence of nausea, 
vomiting, and rescue antiemetics used. Postoperative pain was assessed using a visual 
analog scale (VAS). Also, any extrapyramidal side effects were noted.  
 The results are summarized in Appendix D-2. Group S had 49 patients (65%) who 
experienced PONV; Group D had 28 patients (36%); Group H had 27 patients (37%); 
Group Dx had 28 patients (38%); and Group H + Dx had the lowest incidence where 14 
patients (19%) experienced PONV (p = 0.05). There was no statistical difference between 
Group H, Group Dx and Group D. All of the groups experienced less PONV than Group 
S. There was no statistical difference in postoperative pain scores between groups. 
Extrapyramidal side effects were seen in Group D, where two patients experienced motor 
restlessness and Group H where one patient experienced it. There was no statistical 
difference between any of the groups. A limitation of this study was that the authors did 
not utilize a VAS to score patients’ nausea intensity, making the results less sensitive.  
The critical appraisal for this study can be found in Appendix E-2. This study was 
a randomized double-blind trial. All groups were similar in the beginning of this trial and 
all participants were accounted for at the end. It had a large sample size of 400 people 
and demonstrated that haloperidol decreased nausea and vomiting. This study did address 
the focus areas.  
 Feng et al. (2009) evaluated the prophylactic effect of haloperidol plus 
ondansetron on PONV with patients undergoing laparoscopic cholecystectomies. The 
design of this study is summarized in Appendix C-3. This was a clinical double-blind 
randomized control trial. There were 210 patients to begin this trial, with 18 of them 
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excluded. The patients were divided up into three groups. Group H patients were 
medicated with saline and haloperidol. Group O patient were medicated with ondansetron 
and saline. Group H + O patients were medicated with haloperidol and ondansetron. The 
anesthesia, mechanical ventilation, and surgical technique were all standardized 
throughout. Standard monitoring as well as QTc intervals were recorded. All of the 
patients were monitored for 24 hours postoperatively. The authors recorded the incidence 
and severity of PONV, the severity of postoperative pain, and the occurrence of adverse 
side effects.  
 The results of this study can be seen in Appendix D-3. These authors found that 
Group H + O experienced less PONV than the other groups (p < 0.05). Group H had 25 
patients (39%) experience PONV, Group O had 25 patients (38%), and Group H + O had 
13 patients (21%). The postoperative pain scores were similar in all three groups. Two 
patients out of the study, one in group H and one in group H + O, experienced an adverse 
side effect of restlessness. A limitation in this study was that there was no true control 
group.  
The critical appraisal for this study is summarized in Appendix E-3. This showed 
that the study was a double-blinded study that addressed the focus areas. The sample size 
was 210 people undergoing the same kind of surgery and results demonstrated that 
haloperidol plus ondansetron decreased nausea and vomiting. The findings can be applied 
to similar population groups and the benefits were shown to be worth the harms and 
costs.  
 Joo et al. (2015) conducted a study (Appendix C-4) that evaluated at which dose 
haloperidol could be combined with dexamethasone to prevent PONV without adverse 
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side effects in patients undergoing gynecological laparoscopic procedures. It was a 
clinical double-blind randomized trial. There were 150 patients involved in the study. 
They were divided into three groups with all of the groups were medicated with 
dexamethasone. Group H0 received saline with the dexamethasone; Group H1 received 1 
mg of haloperidol with the dexamethasone; and Group H2 received 2 mg of haloperidol 
with dexamethasone. Anesthesia, ventilation and surgical technique were all 
standardized. The authors monitored the incidence of PONV, pain intensity, rescue 
antiemetics used, and adverse side effects.  
 Groups H1 and H2 had a significantly lower incidence of PONV than Group H0. 
In Group H0 21 patients (42%) experienced PONV; Group H1 11 patients (22%) 
experienced it; and Group H2 had 10 patients (20%) who experienced PONV (p<0.017). 
There were no significant differences in pain scores across all three groups. Group H2 did 
have a significant increase in sedation compared to the other two groups where Group H0 
and Group H1 had an average VAS sedation score of 3.5 and Group H2 had an average 
score of 5 (p < 0.001). There were no cardiac or EPS seen in any of the groups. These 
results are summarized in Appendix D-4. Some limitations of this study were that there 
was no real control group since all patients were medicated with dexamethasone. Also, 
the sample size was relatively small.  
The critical appraisal for this study can be seen in Appendix E-4. This was a 
double-blind randomized study. All groups were similar at the start of the trial and were 
treated equally with the exception of the experimental intervention. All patients were 
accounted for at the end of the study. The sample size was smaller, with 150 patients. It 
did have a precise estimate of the treatment effect showing that haloperidol and 
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dexamethasone decreased nausea and vomiting. These results can be applied to similar 
populations.  
 The study by Wang et al. (2008) evaluated the prophylactic effect of low-dose 
haloperidol on post-operative nausea and vomiting in women undergoing ambulatory 
laparoscopic surgery. The design of this study is summarized in Appendix C-5. It was a 
randomized double-blind and placebo-controlled study. There was a total of 150 patients 
in the study, and they were divided into three groups. There was a saline group, which 
was medicated with saline; a haloperidol group that was medicated with 1 mg of 
haloperidol; and a droperidol group which was medicated with 0.625 mg of droperidol. 
The anesthesia and surgical procedures were standardized. The medications were all 
given 15 minutes after induction of anesthesia. The authors recorded the intensity of the 
postoperative pain using a VAS scale 0-10. The incidence of PONV was collected by 
telephone 24 hours postoperatively. All patients were monitored for any adverse side 
effects.  
 The results of this study can be seen in Appendix D-5. The haloperidol and 
droperidol group both experienced significantly less PONV than the saline group. In the 
haloperidol group 14 patients (31%) experienced PONV; the droperidol group had 14 
patients (32%) and the saline group had 29 patients (62%) who experienced PONV 
(p<0.05). There were no differences found in postoperative pain scores between the 
groups. There was no difference in sedation scores and no EPS were noted. A limitation 
of this study was that since it was done with ambulatory surgery the authors had to rely 
on getting information over the telephone after the patient was discharged and it was not 
done under direct observation.  
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The critical appraisal table for this study is found in Appendix E-5. This study 
was a randomized double-blind study. All participants were treated similarly aside from 
the experimental intervention. It was a relatively small sample size with 150 participants. 
This study did show a precise treatment effect with decreased nausea and vomiting. The 
benefits were shown to be worth the harms and costs. 
 The cross-study analysis can be seen in Appendix F. All five studies showed a 
statistically significant decrease in PONV when haloperidol was used to prophylactically 
treat it. Pain scores were not significantly different except for in the study conducted by 
Benevides et al. (2012), which showed a decrease in pain in the group that was medicated 
with haloperidol. Benevides et al. did not identify any adverse side effects of haloperidol 
in their study. The study by Chu et al. (2008) noted two patients who experienced the 
EPS symptom of motor restlessness; Feng et al. (2009) also noted two patients in their 
study experienced motor restlessness. In the study by Joo et al. (2015), there were no 
extrapyramidal side symptoms (EPS) noted; however, in groups medicated with 2 mg of 
haloperidol there was increased sedation levels. Wang et al. (2008) stated there were no 
adverse side effects of haloperidol noted. Overall, the studies all concluded that 
haloperidol can be used safely as a medication to prophylactically treat PONV.  
 The next section will discuss the summary and conclusions.  
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Summary and Conclusions 
 Postoperative nausea and vomiting is a continuous problem that affects up to 30% 
of all patients undergoing general anesthesia (Pierre & Whelan, 2013).  This complication 
can increase recovery time and length of stay for the patients. This is very uncomfortable 
for the patients and has led to decreased satisfaction scores (Flood et al., 2015). It can 
also be dangerous for the patient putting them at risk for wound dehiscence and aspiration 
(Nagelhout & Plaus, 2014). There are many identified risk factors for PONV. The patient 
specific risk factors are female gender, age less than 50, nonsmokers and a history of 
PONV or motion sickness (Nagelhout & Plaus). Patients who are at determined to be at 
high risk for PONV have an 80% chance of experiencing it (Pierre & Whelan, 2013). 
This is why it is so important to prevent a patient from experiencing this complication.  
 Currently, a prophylactic approach to preventing PONV is being used. The 
vomiting center of the brain can be found in the NTS and there are several different 
neurotransmitters that control the activity in the vomiting center. There is also the 
chemoreceptor trigger zone which detects noxious chemicals (Flood et al., 2015). 
Because PONV can be triggered so many different ways, there are a number of ways that 
we can prevent it. It has been shown that many medications can prevent PONV by 
working on different receptor sites, but that when they are used in combination with each 
other they can have an additive effect (Pierre & Whelan, 2013). One medication that is 
being used to prophylactically treat PONV is haloperidol. This medication is an 
antagonist of the D2 dopamine receptor, preventing PONV at the vomiting center (Flood 
et al.).  
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 This systematic review evaluated randomized control trials that examined how 
haloperidol worked as a prophylactic agent of PONV. The PRISMA framework was used 
as a theoretical framework to guide the selection of the articles used in the systematic 
review. CASP was used to critically appraise each study. PubMed, CINAHL, and 
Medline were searched for haloperidol, postoperative nausea and vomiting, and 
laparoscopic surgery. Once the inclusion and exclusion criteria were applied, there were 
five articles that were included in this systematic review. Each study was evaluated and 
data were collected in two tables and the CASP table.  
 The main findings of this systematic review showed that haloperidol was 
successful in reducing PONV. Every study showed that this medication can significantly 
reduce the number of vomiting episodes and accounts of nausea reported. Some of the 
articles discussed the side effects of haloperidol, and the occurrence of these was not 
found to be statistically significant. Over all, the studies showed that using haloperidol in 
a multimodal approach to prevent PONV was even more successful than using one 
medication alone.  
 These findings can be directly applied to similar populations of patients 
undergoing general anesthesia and directly answers the focus problem. There are some 
limitations to this systematic review. There was a limited number of studies included in 
this systematic review. Also, most of the studies that were included had a limited sample.  
 In conclusion, this systematic review supports the use of haloperidol as a 
medication to be used in preventing PONV. The studies found haloperidol works better 
when being used in a multimodal approach with other prophylactic medications for 
PONV. The next section of this paper will discuss the implications in nursing practice.  
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Recommendations and Implications for Advanced Nursing Practice 
This systematic review yielded information that can be utilized specifically in 
advanced nursing practice. Postoperative nausea and vomiting is a problem that every 
anesthesia provider must consider when administering general anesthesia. Part of the 
nurse anesthetist role as an advanced provider is to make critical thinking decisions and 
provide the best possible care to each patient. Prophylactically treating a patient with a 
multimodal approach the incidence of PONV can be greatly decreased. The multimodal 
approach should be implanted in anesthesia provider practice to provide better patient 
outcomes.  
For an anesthesia provider to utilize haloperidol as one medication in a 
prophylactic approach, they need to understand the mechanism of action, efficacy and 
possible side effects. Providers should also understand the pathophysiology of PONV and 
the risk factors so that they can identify patients that are more likely to suffer from 
PONV. Educating anesthesia providers on PONV, a prophylactic multimodal approach to 
prevent PONV, and specific medications such as haloperidol is needed.  
 CRNA’s can be instrumental in developing and implementing evidence-based 
guidelines to prevent PONV. Utilizing a risk scoring system, such as the Apfel risk score, 
to identify patients at high risk of PONV should be a standardized practice since patients 
at high risk of PONV have an incidence of up to 80%. Guidelines should discuss a 
prophylactic approach with two or more medications for these patients and haloperidol 
should be one of the standardized options. Every medication choice must be patient 
specific but having guidelines and options can help educated practitioners make the best 
decisions.  
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 Further research is needed on this topic. There are many medications that can be 
utilized for prevention of PONV, with new ones being developed. Studies to determine 
how effective and safe each of these medications are should be routinely performed.  
Also, this systematic review specifically evaluated studies that involved laparoscopic 
surgical procedures yet PONV is a possible complication of all general surgeries. The 
efficacy of haloperidol and other antiemetic medications should be studied on all kinds of 
general surgery.   
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Appendix A 
PRISMA 2009 Flow Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(PRISMA Transparent Reporting of Systematic Reviews and Meta-Analyses, 2015) 
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Appendix B 
 
 
Section/topic  # Checklist item  Reported on page #  
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility 
criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions 
and implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, 
comparisons, outcomes, and study design (PICOS).  
 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide 
registration information including registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, 
language, publication status) used as criteria for eligibility, giving rationale.  
 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify 
additional studies) in the search and date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be 
repeated.  
 
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, 
included in the meta-analysis).  
 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any 
processes for obtaining and confirming data from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and 
simplifications made.  
 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was 
done at the study or outcome level), and how this information is to be used in any data synthesis.  
 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of 
results  
14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
 
Risk of bias 
across studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
 
Additional 
analyses  
16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions 
at each stage, ideally with a flow diagram.  
 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
 
Risk of bias 
within studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of 
individual studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
 
Synthesis of 
results  
21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias 
across studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional 
analysis  
23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance 
to key groups (e.g., healthcare providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of 
identified research, reporting bias).  
 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for 
the systematic review.  
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(PRISMA Transparent Reporting of Systematic Reviews and Meta-Analyses, 2015). 
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Appendix C 
 
C-1: Benevides, M. L., Oliveira, S., & Aguilar-Nascimento, J. E., (2012). Combination of haloperidol, 
dexamethasone, and ondansetron reduces nausea and pain intensity and morphine consumption after laparoscopic 
sleeve gastrectomy. Revista Brasileira De Anestesiologia, 63(5), 404-409.  
Purpose 
 
To evaluate the 
intensity of nausea 
and pain and the 
number of 
vomiting episodes 
in postoperative 
patients. 
 
Design 
 
A clinical double-
blind randomized 
control trial with 
three groups, each 
with 30 patients. 
Group O received 
ondansetron only; 
Group DO 
received 
dexamethasone 
and ondansetron; 
Group HDO 
received 
haloperidol, 
dexamethasone, 
and ondansetron 
 
Sample 
 
90 Patients were 
included in total. 
They were all 
greater than 18 
years old, a mix of 
males and females 
and BMI >35. 
ASA levels I – III 
were included. 
 
Surgical Procedure  
 
Laparoscopic 
sleeve 
gastrectomy. 
 
Method 
  
Anesthetic technique was 
standardized with induction 
and maintenance medications 
based on ideal body weight.  
Surgical technique was 
standardized.  
Postoperative diet was 
standardized based on patient’s 
acceptance.  
The Verbal numeric scale of 
nausea (VNSN) and the verbal 
numeric scale of pain (VNSP) 
were utilized to evaluate 
nausea and pain.  
Nausea and pain were 
evaluated 2, 12, 24, and 36 
hours postoperatively. 
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C-2: Chu, C., Shieh, J., Tzeng, J., Chen, J., Lee, Y., Ho, S., & Wang, J. (2008). The prophylactic effect of haloperidol plus 
dexamethasone on postoperative nausea and vomiting in patients undergoing laparoscoically assisted vaginal 
hysterectomy. Ambulatory Anesthesiology, 106(5), 1402-1406. 
Purpose 
To evaluate the 
prophylactic effect 
of haloperidol 
given alone or in 
combination with 
dexamethasone on 
PONV. 
 
 
 
 
 
 
 
 
 
 
 
 
Design 
A clinical double-
blind randomized 
control trial with a 
control group. 
There were five 
groups, each with 
80 patients. Group 
S received a 
placebo. Group D 
received 
droperidol. Group 
H received 
haloperidol. Group 
Dx received 
dexamethasone. 
And Group H + 
Dx received 
haloperidol and 
dexamethasone. 
 
Sample 
A total of 400 
patients, all 
women. All 
patients were ASA 
level I or II. 
Exclusion criteria 
included difficult 
airway, obesity, 
pregnancy, 
psychiatric illness, 
major organ 
disease. 28 of the 
400 patients 
enrolled were 
excluded from the 
analysis. 
Surgical Procedure  
Laparoscopic-
assisted vaginal 
hysterectomy. 
 
Method 
Patients were medicated 15 minutes 
after the induction of anesthesia. 
Anesthesia was standardized for all 
patients. Ventilation was controlled 
mechanically and adjusted to 
maintain end-tidal carbon dioxide.  
Standard monitoring was used and 
QT intervals were measured. 
Patients were observed 
postoperatively for 24 hours. The 
incidence and severity of PONV 
were documented including the 
incidence of nausea, vomiting, 
nausea and vomiting, and rescue 
antiemetics used. Postoperative pain 
was assessed 24 hours 
postoperatively using the visual 
analog scale (VAS). All 
extrapyramidal side effects noted in a 
24 hour period were documented. 
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C-3: Feng, P., Chu, K., Lu, I., Shieh, J., Tzeng, J., Ho, S., … Chu, C. (2009). Haloperidol plus ondansetron prevents 
postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Taiwan, 
47(1), 3-9. 
Purpose 
To evaluate the 
prophylactic effect 
of haloperidol plus 
ondansetron on 
PONV. 
 
Design 
A clinical double-
blind randomized 
control trial. There 
were three groups. 
Group H was 
medicated with 
saline and 
haloperidol; Group 
O was medicated 
with ondansetron 
and saline; Group 
H + O was 
medicated with 
haloperidol and 
ondansetron.  
 
Sample 
A total of 210 
patients. Each 
group had 70 
patients. All 
patients were ASA 
class I or II. 
Exclusion criteria 
included evidence 
of a difficult 
airway, obesity, 
pregnancy, 
psychiatric illness, 
major organ 
disease, QTc 
interval >440, or 
consumption of 
antiemetics within 
24 hours of the 
study. 18 of the 
210 patients were 
excluded. 
Surgical Procedure  
Laparoscopic 
Cholecystectomy. 
 
Method 
Anesthesia was standardized in 
all patients. Ventilation was 
mechanically controlled and 
adjusted to maintain end-tidal 
carbon dioxide. QTc intervals 
were measured during the 
procedure.  
All patients were observed for 
24 hours postoperative. The 
incidence and severity of 
PONV, the severity of 
postoperative pain, and the 
occurrence of postoperative 
adverse effects such as sedation 
and EPS were all recorded.  
Nausea was measure with a 
verbal rating scale from 0-10. 
Episodes of vomiting was either 
retching or expulsion of stomach 
contents. Postoperative pain was 
scaled using a visual analog 
scale from 0-10.  
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C-4: Joo, J., Park, Y., Baek, J., & Moon, Y. (2015). Haloperidol dose combined with dexamethasone for ponv 
prophylaxis in high-risk patients undergoing a gynecological laparoscopic surgery: a prospective, randomized, double-
blind, dose-response and placebo-controlled study. BMC Anesthesiology, 15(99), 1-6. 
Purpose 
To identify which 
dose of 
haloperidol could 
be combined with 
dexamethasone 
without adverse 
effects to prevent 
PONV in high-risk 
patients.  
 
Design 
A clinical double-
blind randomized 
control trial with a 
control group. 
Patients were 
divided up into 
three groups. All 
of the groups were 
medicated with 
dexamethasone. 
Group H0 was 
medicated with 
saline; Group H1 
medicated with 1 
mg of haloperidol; 
Group H2 was 
medicated with 2 
mg haloperidol.  
 
Sample 
There was a total 
of 150 female 
adult patients 
involved in this 
study. They were 
all ASA class I or 
II, ages between 
20-65. All patients 
were non-smokers 
and used opioids 
for postoperative 
pain control. One 
patient was 
excluded due to 
intraoperative 
conversion to an 
open laparotomy. 
Surgical Procedure  
Gynecological 
laparoscopic 
surgeries. 
 
Method 
Anesthesia was standardized, 
titrated to maintain a BIS value of 
40-60. All patients received 5 mg 
dexamethasone IV during 
induction. Ventilation was 
controlled mechanically and 
adjusted to maintain end-tidal 
carbon dioxide 30-40. Haloperidol 
was administered approximately 
30 min before the end of 
anesthesia. All patients were given 
a PCA for postoperative pain 
control.  
The authors monitored the 
incidence of postoperative nausea 
and vomiting, pain intensity, 
rescue antiemetics used, and 
adverse side effects. Nausea was 
graded as tolerable or intolerable. 
Postoperative pain was measured 
using a visual analogue scale from 
0-10. Sedation was assessed on a 
VAS scale 0-10.  
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C-5: Wang, T., Liu, Y., Chu, C., Shieh, J., Tzeng, J., & Wang, J. (2008). Low-dose haloperidol prevents post-operative 
nausea and vomiting after ambulatory laparoscopic surgery. Acta Anaesthesiologica Scandinavica, 52, 280-284. 
Purpose 
To evaluate the 
prophylactic effect 
of low-dose 
haloperidol on 
post-operative 
nausea and 
vomiting in 
women. 
 
Design 
A randomized, 
double-blind and 
placebo-controlled 
study. There were 
three groups, each 
with 50 patients. 
The Haldol group 
was medicated 
with 1 mg of 
Haldol. The 
droperidol group 
was medicated 
with 0.625 mg of 
droperidol. The 
saline group 
received saline.  
 
Sample 
A total of 150 
patients, all 
women, were 
involved in this 
study. Each group 
had 50 patients. 
All patients were 
ASA class I or II.  
14 patients were 
excluded during 
the study due to 
surgical reasons or 
incomplete data 
after the patients 
left the hospital. 
Surgical Procedure  
Ambulatory 
laparoscopic 
surgery. 
 
Method 
The anesthesia regimen and the 
surgical procedure were 
standardized. Ventilation was 
controlled mechanically and adjusted 
to maintain an end-tidal carbon 
dioxide level of 30-40. The Haldol, 
droperidol, or saline was 
administered 15 minutes after 
induction of anesthesia.  
The intensity of postoperative pain 
was measured using a visual 
analogue scale of 0-10. The presence 
of PONV was collected by telephone 
24 hours after surgery. The 
researchers monitored for adverse 
side effects.  
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Appendix D 
D-1:  Benevides, M. L., Oliveira, S., & Aguilar-Nascimento, J. E., (2012). Combination of haloperidol, dexamethasone, and 
ondansetron reduces nausea and pain intensity and morphine consumption after laparoscopic sleeve gastrectomy. Revista 
Brasileira De Anestesiologia, 63(5), 404-409. 
 
Nausea and Vomiting 
 
The mean intensity of nausea 
through the VNSN for Group 
O was 4; Group DO it was 
2.1; Group HDO it was 1.5 
(p = 0.001). 
Group HDO experienced 
0.63 ± 1.2 episodes of 
vomiting compared to group 
O 1.10 ± 1.2, and group DO 
0.83 ± 2 (p = 0.052). 
 
Pain Scores  
 
The mean intensity of pain 
through the VNSP for group 
O was 2.2; Group DO it was 
1.9; Group HDO it was 1 (p 
= 0.046). 
 
Adverse Side Effects 
 
This study did not monitor 
for adverse side effects.  
Limitations 
 
There was not a control 
group for this experiment. 
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D-2: Chu, C., Shieh, J., Tzeng, J., Chen, J., Lee, Y., Ho, S., & Wang, J. (2008). The prophylactic effect of haloperidol plus 
dexamethasone on postoperative nausea and vomiting in patients undergoing laparoscopically assisted vaginal hysterectomy. 
Ambulatory Anesthesiology, 106(5), 1402-1406. 
Postoperative Nausea and 
Vomiting 
 
In Group S, 49 patients 
(65%) experienced PONV. 
In Group D, 28 patients 
(36%); Group H 27 patients 
(37%); Group Dx 28 patients 
(38%); Group H + Dx 14 
patients (19%) experienced 
PONV (p = 0.05). 
 
Pain Scores  
 
 
All groups reported VAS 
scores of 2-4 on a scale of 0-
10. There was no significant 
differences determined 
between groups. 
 
Adverse Side Effects 
 
 
Group D had two patients 
that experienced EPS, motor 
restlessness. Group H had 
one patient that experienced 
motor restlessness. No 
statistical significant 
differences were determined 
between groups. 
Limitations 
 
 
The results are not sensitive 
enough to detect the anti-
nausea effect of the 
antiemetics tested because 
the authors did not use a 
VAS score to evaluate the 
nausea severity. 
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D-3:  Feng, P., Chu, K., Lu, I., Shieh, J., Tzeng, J., Ho, S., … Chu, C. (2009). Haloperidol plus ondansetron prevents 
postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Taiwan, 47(1), 
3-9. 
Postoperative Nausea and 
Vomiting 
Group H had 25 patients 
(39%) experience PONV; 
Group O had 25 patients 
(38%); and Group H + O had 
13 patients (21%) (p<0.05). 
Pain Scores  
Using the VAS, with a score 
range from 0-10, Group H 
scored 2.2 ± 1.4; Group O 
scored 2.1 ± 1.3; Group H + 
O scored 1.9± 0.8. 
 
Adverse Side Effects 
Two patients reported an 
EPS of restlessness. One was 
in Group H, and one was in 
Group H + O. 
Limitations 
No control group was used in 
this study. 
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D-4:   Joo, J., Park, Y., Baek, J., & Moon, Y. (2015). Haloperidol dose combined with dexamethasone for ponv prophylaxis 
in high-risk patients undergoing a gynecological laparoscopic surgery: a prospective, randomized, double-blind, dose-
response and placebo-controlled study. BMC Anesthesiology, 15(99), 1-6. 
Postoperative Nausea and 
Vomiting 
In Group H0 21 patients 
(42%) experienced PONV; 
Group H1 had 11 patients 
(22%); and Group H2 had 10 
patients (20%) who 
experienced PONV 
(p<0.017). 
Pain Scores  
 
 Group H0 reported an 
average VAS score of 2.2; 
Group H1 reported 2.8; 
Group H2 reported 2.2. 
Adverse Side Effects 
 
 There was no significant 
difference in sedation scores 
between Group H0 and H1, 
average on the VAS score 
was a 3.5. There was an 
increased sedation scores in 
Group H2, where the average 
VAS score was a 5 
(p<0.001). No cardiac 
arrhythmias or EPS were 
observed. 
Limitations 
 
 There was no control group, 
as all patients received 
dexamethasone.  
Relatively small sample size, 
leading to these results being 
exploratory rather than 
confirmatory results. 
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D-5: Wang, T., Liu, Y., Chu, C., Shieh, J., Tzeng, J., & Wang, J. (2008). Low-dose haloperidol prevents post-operative 
nausea and vomiting after ambulatory laparoscopic surgery. Acta Anaesthesiologica Scandinavica, 52, 280-284. 
Postoperative Nausea and 
Vomiting 
In the haloperidol group 14 
patients (31%) experienced 
PONV; the droperidol group 
had 14 patients (32%) and 
the saline group had 29 
patients (62%) who 
experienced PONV (p<0.05). 
Postoperative Pain Score 
 
Pain reports were 1-3 in all 
three groups with no 
differences found between 
them.  
Adverse Side Effects 
 
 The level of sedation was 
scored 1-2 in all three 
groups, with no differences 
found. There were no 
observed EPS in any group. 
Limitations 
 
Due to the fact that this study 
was done with ambulatory 
surgery, the authors had to 
rely on getting information 
on the phone after the patient 
was discharged and not 
actual observed results. 
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Appendix E 
 
Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
E-1: Benevides, M. L., Oliveira, S., & Aguilar-Nascimento, J. E., (2012). Combination 
of haloperidol, dexamethasone, and ondansetron reduces nausea and pain intensity and 
morphine consumption after laparoscopic sleeve gastrectomy. Revista Brasileira De 
Anestesiologia, 63(5), 404-409. 
A) Are the results of the trial valid? 
 
YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused 
issue? 
X   
2. Was the assignment of patients to 
treatments randomized? 
X   
3. Were all of the patients who entered the 
trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers and study 
personnel “blind” to treatment? 
X   
5. Were the groups similar at the start of 
the trial? 
X   
6. Aside from the experimental 
intervention, were the groups treated 
equally? 
X   
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
 
Not discussed. 
 
8. How precise was the estimate of the 
treatment effect? 
 
 
Not discussed. 
 
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your 
context?  
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
  X 
11. Are the benefits worth the harms and 
costs?    
X   
Note. This study did not mention if there were any adverse side effects of haloperidol 
noted. 
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
E-2: Chu, C., Shieh, J., Tzeng, J., Chen, J., Lee, Y., Ho, S., & Wang, J. (2008). The 
prophylactic effect of haloperidol plus dexamethasone on postoperative nausea and 
vomiting in patients undergoing laparoscopically assisted vaginal hysterectomy. 
Ambulatory Anesthesiology, 106(5), 1402-1406. 
A) Are the results of the trial valid? 
 
YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused 
issue? 
X   
2. Was the assignment of patients to 
treatments randomized? 
X   
3. Were all of the patients who entered the 
trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers and study 
personnel “blind” to treatment? 
X   
5. Were the groups similar at the start of 
the trial? 
X   
6. Aside from the experimental 
intervention, were the groups treated 
equally? 
X   
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
 
Not discussed. 
 
 
8. How precise was the estimate of the 
treatment effect? 
 
 
Not discussed. 
 
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your 
context?  
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
X   
11. Are the benefits worth the harms and 
costs?    
X   
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
E-3: Feng, P., Chu, K., Lu, I., Shieh, J., Tzeng, J., Ho, S., … Chu, C. (2009). 
Haloperidol plus ondansetron prevents postoperative nausea and vomiting in patients 
undergoing laparoscopic cholecystectomy. Acta Anaesthesiol Taiwan, 47(1), 3-9. 
A) Are the results of the trial valid? 
 
YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused 
issue? 
X   
2. Was the assignment of patients to 
treatments randomized? 
X   
3. Were all of the patients who entered the 
trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers and study 
personnel “blind” to treatment? 
X   
5. Were the groups similar at the start of 
the trial? 
X   
6. Aside from the experimental 
intervention, were the groups treated 
equally? 
X   
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
 
Not discussed. 
 
 
8. How precise was the estimate of the 
treatment effect? 
 
 
Not discussed. 
 
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your 
context?  
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
X   
11. Are the benefits worth the harms and 
costs?    
X   
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
E-4:   Joo, J., Park, Y., Baek, J., & Moon, Y. (2015). Haloperidol dose combined with 
dexamethasone for ponv prophylaxis in high-risk patients undergoing a gynecological 
laparoscopic surgery: a prospective, randomized, double-blind, dose-response and 
placebo-controlled study. BMC Anesthesiology, 15(99), 1-6. 
A) Are the results of the trial valid? 
 
YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused 
issue? 
X   
2. Was the assignment of patients to 
treatments randomized? 
X   
3. Were all of the patients who entered the 
trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers and study 
personnel “blind” to treatment? 
X   
5. Were the groups similar at the start of 
the trial? 
X   
6. Aside from the experimental 
intervention, were the groups treated 
equally? 
X   
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
 
Not discussed. 
 
 
8. How precise was the estimate of the 
treatment effect? 
 
 
Not discussed. 
 
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your 
context?  
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
X   
11. Are the benefits worth the harms and 
costs?    
X   
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Critical Appraisal Skills Programme (CASP) Randomized Control Trials Checklist 
E-5: Wang, T., Liu, Y., Chu, C., Shieh, J., Tzeng, J., & Wang, J. (2008). Low-dose 
haloperidol prevents post-operative nausea and vomiting after ambulatory laparoscopic 
surgery. Acta Anaesthesiologica Scandinavica, 52, 280-284. 
A) Are the results of the trial valid? 
 
YES CAN’T 
TELL 
NO 
1. Did the trial address a clearly focused 
issue? 
X   
2. Was the assignment of patients to 
treatments randomized? 
X   
3. Were all of the patients who entered the 
trial properly accounted for at its 
conclusion? 
X   
4. Were patients, health workers and study 
personnel “blind” to treatment? 
X   
5. Were the groups similar at the start of 
the trial? 
X   
6. Aside from the experimental 
intervention, were the groups treated 
equally? 
X   
 
B) What are the results? 
 
7. How large was the treatment effect?   
 
 
Not discussed. 
 
 
8. How precise was the estimate of the 
treatment effect? 
 
 
Not discussed. 
 
C) Will the results help locally? YES CAN’T 
TELL 
NO 
9. Can the results be applied in your 
context?  
(or to the local population?) 
X   
10. Were all clinically important outcomes 
considered? 
X   
11. Are the benefits worth the harms and 
costs?    
X   
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Appendix F 
 
Cross-Study Results Analysis 
Study number Nausea & Vomiting Pain Scores Adverse Side Effects 
1 There was a decrease in nausea 
intensity and episodes of vomiting 
in the group medicated with 
haloperidol.  
 
There was a decrease in VAS 
pain scores in the group 
medicated with haloperidol. 
 
None noted in this study. 
2 There was a decrease in PONV 
when patients were medicated with 
haloperidol, droperidol, or 
dexamethasone. There was a further 
decrease when they were medicated 
with haloperidol and 
dexamethasone together.  
 
There was no statistical 
difference between groups in 
reported pain scores. 
Two patients experienced the 
EPS of motor restlessness. 
3 There was a significant decrease in 
patients medicated with 
ondansetron and haloperidol 
combined. 
There was no statistical 
difference between groups in 
reported pain scores. 
 
Two patients experienced the 
EPS of motor restlessness. 
4 There was a decrease in PONV 
when patients were medicated with 
haloperidol. 
There was no statistical 
difference between groups in 
reported pain scores. 
 
There were no EPS noted, the 
haloperidol group with higher 
dosing did experienced 
increased sedation. 
 
5 There was a decreased in PONV 
when patients were medicated with 
haloperidol or droperidol compared 
to saline.  
There was no statistical 
difference between groups in 
reported pain scores. 
No adverse side effects 
observed in this study. 
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